Neurofibromatosis Type 1 (NF1)

Neurofibromatosis Type 1 (NF1)

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Neurofibromatosis Type 1 (NF1) is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • neurofibroma, multiple
  • neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome
  • peripheral neurofibromatosis
  • Recklinghausen's phakomatosis
  • Von Recklinghausen's disease
  • Von Recklinghausen's neurofibromatosis
  • NF1

Disorder Subdivisions

  • segmental neurofibromatosis

General Discussion

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas) and areas of abnormally decreased or increased coloration (hypo- or hyperpigmentation) of the skin. Areas of abnormal pigmentation typically include pale tan or light brown discolorations (cafe-au-lait spots) on the skin of the trunk and other regions as well as freckling, particularly under the arms (axillary) and in the groin (inguinal) area. Such abnormalities of skin pigmentation are often evident by one year of age and tend to increase in size and number over time.



At birth or early childhood, affected individuals may have relatively large benign tumors that consist of bundles of nerves (plexiform neurofibromas). Individuals with NF1 may also develop benign tumor-like nodules of the colored regions of the eyes (Lisch nodules) or tumors of the optic nerves (second cranial nerves), which transmit nerve impulses from the innermost, nerve-rich membrane of the eyes (retinas) to the brain. More rarely, affected individuals may develop certain malignant (cancerous) tumors.



NF1 may also be characterized by unusual largeness of the head (macrocephaly) and relatively short stature. Additional abnormalities may also be present, such as episodes of uncontrolled electrical activity in the brain (seizures); learning disabilities; speech difficulties; abnormally increased activity (hyperactivity); and skeletal malformations, including progressive curvature of the spine (scoliosis), bowing of the lower legs, and improper development of certain bones. In individuals with NF1, associated symptoms and findings may vary greatly in range and severity from case to case. Most people with NF1 have normal intelligence but learning disabilities appear in about 50% of children with NF1.



NF1 is caused by changes (mutations) of a relatively large gene on the long arm (q) of chromosome 17 (17q11.2). The gene regulates the production of a protein known as neurofibromin, which is thought to function as a tumor suppressor. In about 50 percent of individuals with NF1, the disorder results from spontaneous (sporadic) mutations of the gene that occur for unknown reasons. In others with the disorder, NF1 is inherited as an autosomal dominant trait.



The name "neurofibromatosis" is sometimes used generally to describe NF1 as well as a second, distinct form of NF known as neurofibromatosis Type II (NF2). Also an autosomal dominant disorder, NF2 is primarily characterized by benign tumors of both acoustic nerves, leading to progressive hearing loss. The auditory nerves (eight cranial nerves) transmit nerve impulses from the inner ear to the brain.

Symptoms

The symptoms of neurofibromatosis type 1 usually appear during childhood. The disorder is progressive and, in some cases, the symptoms become more pronounced during puberty, pregnancy, or when hormonal changes take place. The range and severity of symptoms varies greatly among affected individuals and the rate of progression of this disorder is not predictable.



The first sign of neurofibromatosis type 1 is usually the appearance of multiple brown spots on the skin (cafe-au-lait) and freckling under the arms (axillary) or in the groin area (inguinal). According to the NIH Consensus Conference in 1987, a diagnosis of NF1 requires that there must be six such spots (5 mm in size) before puberty; these spots enlarge to 15mm after puberty. Small clumps of pigment develop on the iris of the eyes (Lisch nodules). The presence of Lisch nodules is highly indicative of NF1 as they occur in 97 percent of affected individuals. Freckling under the arm or in the area of the groin, along with Lisch nodules, are important criteria for the diagnosis of neurofibromatosis type 1.



Multiple tumors (neurofibromas) occur in neurofibromatosis type 1, forming on the nerves on or under the skin or in deeper areas of the body. Pain may or may not occur. Tumors can cause disfigurement and wrap around or penetrate the nerves. Orthopedic problems may develop including curvature of the spine (scoliosis) and a condition called pseudoarthrosis. This condition is characterized by loss of bone tissue (deossification) on weight-bearing long bones, followed by a fracture; the fracture does not form the normal mass of tissues (callus) that usually forms at a fracture site. This is commonly referred to as a "false joint." With pseudoarthrosis the long bones of the legs, especially the tibia, may become thin and bent (bowed), and may fracture easily. These breaks may fail to heal properly. Tumors may also develop on the nerves of the eye (optic gliomas). In a small number of affected individuals, certain types of malignant tumors may develop, especially malignant peripheral nerve sheath tumors.



Sexual development may be delayed or may occur early (precocious puberty) in individuals with neurofibromatosis type 1. In addition, about 50 percent of individuals with NF1 experience learning disabilities. (For more information on this disorder, choose "precocious puberty" as your search term in the Rare Disease Database.)



In the localized form of neurofibromatosis type 1, known as segmental neurofibromatosis, tumors are typically limited to one area of the body.

Causes

In about 50 percent of individuals with NF1, the disorder is inherited from a parent as an autosomal dominant trait. Sporadic or random mutations in the gene responsible for NF1, account for the remaining 50% of cases. The NF1 gene, a remarkably large gene, has been mapped to chromosome 17q11.



Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Human body cells normally have 46 chromosomes. Pairs of human chromosomes are numbered from 1 through 22 and the sex chromosomes are designated X and Y. Males have one X and one Y chromosome and females have two X chromosomes. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome 17q11.2" refers to band 11.2 on the long arm of chromosome 17. The numbered bands specify the location of the thousands of genes that are present on each chromosome.



Genetic diseases are determined by the combination of genes for a particular trait that are on the chromosomes received from the father and the mother.



Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary for the appearance of the disease. The abnormal gene can be inherited from either parent, or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.



According to investigators, the large size of the NF1 gene is consistent with the large percentage of cases resulting from spontaneous (sporadic) changes of the gene. The NF1 gene regulates (encodes for) the production of neurofibromin, a protein that functions as a tumor suppressor. Several different mutations of the NF1 gene have been identified in individuals with the disorder (e.g., deletions, insertions, point mutations). Investigators have determined that some severely affected individuals may have a deletion of the entire NF1 gene as well as deletion of material from other adjacent genes (contiguous genes), potentially contributing to the wide variability of symptoms and findings in those with the disorder.



A localized form of neurofibromatosis type 1 (segmental NF) appears to be caused by a genetic change that is not inherited in the same manner (somatic mutation) as the NF1 gene. The risk for recurrence in the children of people with this form of the disease has not been determined.

Affected Populations

Neurofibromatosis type 1 is a rare disorder that affects males and females in equal numbers. All races and ethnic groups can be affected by this disorder. Neurofibromatosis type 1 is estimated to occur in 1 in 4,000 births. The diagnosis of neurofibromatosis type 1 is usually made during the first decade of life, based on characteristic skin freckling, cafe-au-lait spots, optic glioma, and/or pseudoarthrosis.

Standard Therapies

Diagnosis

Neurofibromatosis type 1 (NF1) is diagnosed if two or more of the following are present:



Six or more cafe-au-lait spots;

Two or more neurofibromas of any type or 1 "plexiform" neurofibroma;

Freckling under the arms (axillary) or in the groin area (inguinal);

Benign tumor of the optic nerve (glioma);

Two or more Lisch nodules in the iris of the eyes;

Lesions in the bone (sphenoid dysplasia or thinning of long bones) with or without pseudoarthrosis;

A parent, sibling, or child with neurofibromatosis Type 1.



Treatment

People with neurofibromatosis type 1 may undergo surgery to remove particularly troublesome tumors. Physical therapy may be beneficial for some people. A variety of orthopedic devices may help to improve mobility in some cases. Other treatment is symptomatic and supportive.



Genetic counseling will be of benefit for people with neurofibromatosis type 1 and their families. For clinical facilities that treat people with neurofibromatosis, please refer to the Resources section of this report.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government website.



For more information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com



The Children's Tumor Foundation launched an NF Registry in 2012. The purpose of this registry is to find people who may be eligible for clinical trials or other research studies being conducted in the field of NF, and to determine the commonality of specific NF characteristics. Please go to www.nfregistry.org for more information.



A Phase I/II trial of PEG12000 Interferon alfa-2b (PEG-Intron) is in progress at several locations. This study is designed to determine the maximum-tolerated dose, toxicity profile, and efficacy of PEG-Intron in NF1 patients with progressively disfiguring or disabling plexiform neurofibromas. For more information on this study, sponsored by Schering-Plough, contact:



Beverly Brannon, Study Coordinator

Phone: (412) 692-7070

Email: Beverly.Brannon@chp.edu



Several NIH studies focusing on children and young adults with NF1 are presently (2004) in progress. The purpose of these studies is to measure the success and safety of the drug Pirfenidone in slowing the growth of, or possibly shrinking, plexiform neurofibromas. For information on these studies, contact the government sources listed at the beginning of this section.



The National Cancer Institute is sponsoring a study of the use of the investigational drug R115777 to treat children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. This study will examine whether the drug can shrink or slow the growth of plexiform neurofibromas, and determine the side effects related to treatment. Patients with NF1 between three and 25 years of age may be eligible for this study. This trial is being conducted at multiple institutions. For more information, contact;



Andrea Gillespie, Study Coordinator

Phone: (301) 402-1848

Email: gillesan@mail.nih.gov



Researchers at the University of Cincinnati are studying tumor growth factors, growth factor receptors, and signaling pathways in neurofibroma cells in individuals with neurofibromatosis type 1. They require neurofibroma tissue from NF1 patients. For more information, contact:



Dr. Nancy Ratner

Phone: (513) 558-6079

Fax: (513) 558-4454

Email: nancy.ratner@uc.edu



A co-founder of the National Neurofibromatosis Foundation, Allan Rubenstein, MD, has founded a drug development company, NexGenix Pharmaceuticals, focused on fighting NF1 and NF2. Information on studies of drug treatments for neurofibromatosis is available at:



Website: www.nexgenixpharm.com

Email: Info@newgenixpharm.com

References

TEXTBOOKS

Short MP. Neurofibromatosis Type 1. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:563-64.



Beers MH, Berkow R., eds. The Merck Manual, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:.



Berkow R., ed. The Merck Manual-Home Edition.2nd ed. Whitehouse Station, NJ: Merck Research Laboratories; 2003:.



Larson DE. ed. Mayo Clinic Family Health Book. New York, NY: William Morrow and Company, Inc; 1996:.



Bennett JC, Plum F. Eds. Cecil Textbook of Medicine. 20th ed. W.B. Saunders Co., Philadelphia, PA; 1996.



REVIEW ARTICLES

Stephens K. Genetics of neurofibromatosis 1-associated peripheral nerve sheath tumors. Cancer Invest. 2003;21:897-914.



Conti P, Pansini G, Mouchaty H, et al. Spinal neurinomas: retrospective analysis and long-term outcome of 179 consecutively operated cases and review of the literature. Surg Neurol. 2004;61:34-43; discussion 44.



Young TL. Ophthalmic genetics/inherited eye disease. Curr Opin Ophthalmol. 2003;14:296-303.



Bryant J, Farmer J, Kessler LJ, et al. Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst. 2003;20:1196-204.



Joyhnson MV. Brain plasticity in paediatric neurology. Eur J Paediatr Neurol. 2003;7:105-13.



Tamer E, Yalcin B, Alli N. Multiple nodular plexiform neurofibromas in a neurofibromatosis 1 family: a familial tendency? A case report and review of the literature. Int J Dermatol. 2003;42:357-58.



Reynolds RM, Browning GG, Nawroz I, et al. Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet. 2003;361:1552-54.



McLaughlin ME, Jacks T. Neurofibromatosis type 1. Methods Mol Biol. 2003;222:223-37.



Kandt RS. Tuberous sclerosis complex and neurofibromatosis type 1: the two most common neurocutaneous diseases. Neurol Clin. 2002;20:941-64.



Abdel-Wanis ME, Kawahara N. Bone development in neurofibromatosis 1. Med Hypotheses. 2003;60:459-62.



Rosser TL, Packer RJ. Neurocognitive dysfunction in children with neurofibromatosis type 1. Curr Neurol Neurosci Rep. 2003;3:129-36.



Ferner RE, O'Doherty MJ. Neurofibroma and schwannoma. Curr Opin Neurol. 2002;15:679-84.



Lynch TM, Gutmann DH. Neurofibromatosis 1. Neurol Clin. 2002;20:841-65.



FROM THE INTERNET

McKusick VA, Ed. Online Mendelian Inheritance in Man (OMIM). The Johns Hopkins University. Neurofibromatosis, Type I; NF1. Entry Number; 162200: Last Edit Date; 2/10/2004.



Friedman JM. Neurofibromatosis 1. GENEReviews. Last Update: 30 September 2002. 21pp.

www.geneclinics.org



Pletcher BA. Neurofibromatosis, Type 1. emedicine. Last Updated: January 25, 2002.

www.emedicine.com/neuro/topic248.htm



Rasmussen SA, Friedman JM. NF1 Gene and Neurofibromatosis Type 1. CDC - Genomics and Disease Prevention. Updated August 31, 1999. 12 pp.

www.cdc.gov/hugenet/reviews/NF1gene.htm



Pinson S. Neurofibromatosis type I or von Recklinghausen's disease. Orphanet. Creation date: May 2002. 11pp.

www.orpha.net/data/patho/GB/uk-NF1.html



Pinson S. Neurofibromatosis type I. Orphanet. May 2002. 2pp.

www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=636



Upadhyaya M, Consoli C, Majounie E, et al. Neurofibromatosis Type 1. Department of Medical Genetics, University of Wales. Last Updated 26 March 2003. 3pp.

www.uwcm.ac.uk/study/medical_genetics/research/nfl/



Huret J-P. Atlas of Genetics and Cytogenetics in Oncology and Haematology. Indexed on: Nov 26 2003. 3pp.

www.infobiogen.fr/services/chromcancer/Kprones/NF1ID10006.html



Neurofibromatosis type 1. AmershamHealth. Encyclopedia of Medical Imaging Volume VII. nd. 3pp.

www.amershamhealth.com/medcyclopaedia/Volume%20VII/NEUROFIBROMATOSIS%20TY.



Neurofibromatosis Type 1. Texas Children's Hospital. nd. 5pp.

www.texaschildneurology.com/Nf1.htm



Neurofibromatosis Type 1 (NF1). Neurofibromatosis Association of Australia, Inc. Last Updated: 7 June 2002. 2pp.

www.nfaa.org.au/resources/nf1.html



Gutmann DH, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-57.

Resources

Children's Tumor Foundation

95 Pine Street

16th Floor

New York, NY 10005-4002

Tel: (212)344-6633

Fax: (212)747-0004

Tel: (800)323-7938

TDD: (212)344-6633

Email: info@ctf.org

Internet: http://www.ctf.org/



March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763

Tel: (888)663-4637

Email: Askus@marchofdimes.com

Internet: http://www.marchofdimes.com



Neurofibromatosis, Inc.

213 S. Wheaton Ave.

Wheaton, IL 60187

USA

Tel: (630)510-1115

Fax: (630)510-8508

Tel: (800)942-6825

Email: admin@nfnetwork.org

Internet: http://www.nfnetwork.org



Neurofibromatosis Clinic at Texas Children's Hospital

6701 Fannin Street, #1560

Houston, TX 77030

Tel: (832)822-4280

Tel: (800)364-5437

Email: plunkett@bcm.edu

Internet: http://www.texaschildrens.org/Locate/Departments-and-Services/Genetic-Disorders/Neurofibromatosis-Clinic/



Cedars-Sinai Medical Genetics Institute

8700 Beverly Blvd

PACT Suite 400

Los Angeles, CA 90048

USA

Tel: (310)423-9914

Fax: (310)423-2080

Tel: (800)233-2771

Internet: http://www.cedars-sinai.edu/Patients/Programs-and-Services/Medical-Genetics-Institute/



Neurofibromatosis Clinic

The Children's Hospital of Philadelphia

34th Street and Civic Center Boulevard

Room 9028

Philadelphia, PA 19104

Tel: (215)590-2920

Tel: (800)879-2467

Internet: http://www.chop.edu/healthinfo/fibromatosis-and-desmoid-tumors.html or http://www.chop.edu/service/neurofibromatosis/home.html



Children's National Medical Center

Genetics Department

Attn: Kenneth Rosenbaum MD

111 Michigan Ave. NW

Suite 1950

Washington, DC 20010

Tel: (202)476-2327

Tel: (888)884-2327

Email: tbear@cnmc.org

Internet: http://www.childrensnational.org/



NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801

Bethesda, MD 20824

Tel: (301)496-5751

Fax: (301)402-2186

Tel: (800)352-9424

TDD: (301)468-5981

Internet: http://www.ninds.nih.gov/



Massachusetts General Hospital Neurofibromatosis Clinic

15 Parkman St. 8th Floor, Room 835

Boston, MA 02114

USA

Tel: (617)724-7856

Fax: (617)724-8769

Email: SPlotkin@partners.org

Internet: http://neurosurgery.mgh.harvard.edu/NFclinic/



New England Consortium of Metabolic Programs

Children's Hospital Boston

1 Autumn Street, Room 525

Boston, MA 02115

USA

Tel: (617)355-7346

Fax: (617)730-0907

Email: vera.anastasoaie@childrens.harvard.edu_

Internet: http://www.newenglandconsortium.org



Comer Children's Hospital - University of Chicago (Neurofibromatosis Clinic)

Pediatric Neurology

5721 S. Maryland Avenue, MC3055

Chicago, IL 60637

USA

Tel: (773)834-8064

Fax: (773)702-4786

Email: cmacmill@peds.bsd.uchicago.edu

Internet: http://www.uchicagokidshospital.org/specialties/neurology/patient-guides/neurofibromatosis/



BC Neurofibromatosis Foundation

Box 5339

Victoria, BC, V8R 6S4

Canada

Tel: 800385BCNF (2263)

Email: info@bcnf.bc.ca

Internet: http://www.bcnf.bc.ca



Rare Cancer Alliance

1649 North Pacana Way

Green Valley, AZ 85614

USA

Internet: http://www.rare-cancer.org



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org



Let Them Hear Foundation

1900 University Avenue, Suite 101

East Palo Alto, CA 94303

Tel: (650)462-3174

Fax: (650)462-3144

Email: info@letthemhear.org

Internet: http://www.letthemhear.org



Alberta Neurofibromatosis Association

636 Hunterfield Place NW

Calgary

Alberta, T2K 4L6

Canada

Tel: 4032754894

Tel: 8669392263

Email: pam@albertanf.org or cathy@albertanf.org

Internet: http://www.albertanf.org



Cancer.Net

American Society of Clinical Oncology

2318 Mill Road Suite 800

Alexandria, VA 22314

Tel: (571)483-1780

Fax: (571)366-9537

Tel: (888)651-3038

Email: contactus@cancer.net

Internet: http://www.cancer.net/



Medical Home Portal

Dept. of Pediatrics

University of Utah

P.O. Box 581289

Salt Lake City, UT 84158

Tel: (801)587-9978

Fax: (801)581-3899

Email: mindy.tueller@utah.edu

Internet: http://www.medicalhomeportal.org



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.